ClinicalTrials.gg
Not yet recruitingNCT07941284Updated Nov 17, 2026

Five-Year Multicenter Cohort Study of Vaginal Microbiome and STIs Progression

An observational study in STIs, sponsored by Shenzhen Maternity & Child Healthcare Hospital. Not yet recruiting at 43 sites in China. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shenzhen Maternity & Child Healthcare Hospital · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,574
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Sexually Transmitted Diseases with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Sexually Transmitted Diseases · China.

Started
2026
the only one that year
Observational
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Shenzhen Maternity & Child Healthcare Hospital

Among the 11 studies in Sexually Transmitted Diseases with a site in China, this one is the only one that started in 2026, is one of 4 observational ones, and was the 11th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

2 of the 11 studies in Sexually Transmitted Diseases with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Sexually Transmitted Diseases with a site in China, or all of them as a file.
02

Study summary

  1. To elucidate the long-term impact of vaginal microbiome and the dynamic trends of its characteristics across 5 years follow-up visits on the clinical outcomes of sexually transmitted infections (STIs).
  2. To determine the long-term effects of specific microbial infections (Up6, MH) and vaginal microbiome characteristics on the progression of STIs.
Read the detailed description

This multicenter, observational study is a 5-year longitudinal follow-up extending the CALM2004 cohort. It aims to enroll 7,574 women aged 18-60 to investigate the long-term impact of vaginal microbiome characteristics and sexually transmitted infections (STIs) on cervical lesion progression. By collecting vaginal secretions, and blood samples, the study will evaluate the 5-year cumulative incidence of CIN2+ and determine how specific microbial infections (e.g., Up6, MH) influence clinical outcomes, providing high-level evidence for cervical cancer prevention strategies.

03

Conditions studied

  • STIs

Keywords

  • Vaginal microbiome, HPV, STIs, Cervical lesion, Hormones
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 7,574 women aged 18-60 years who previously participated in the baseline of the CALM2004 multicenter cohort study will be recruited for this 5-year longitudinal follow-up. This is a multicenter study, and participants will be recruited through targeted invitations from the research team members. The study population consists of women with a broad spectrum of baseline vaginal microecological statuses and varying risks of STIs and cervical lesions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged 18 to 60 years.
  2. Participants who previously participated in the baseline of the CALM2004 study.
  3. Volunteers who are recruited through targeted invitations and consent to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women.
  2. Received treatment for reproductive tract infections or sexually transmitted infections (STIs) within the past month.
  3. Used broad-spectrum antibiotics, local genital probiotics, or vaginal suppositories within the past month.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,574 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • CALM2004 Follow-up Cohort

    A total of 7,574 women aged 18-60 who previously participated in the CALM2004 baseline study will be enrolled for a 5-year longitudinal follow-up. Participants will undergo comprehensive assessments including questionnaires, vaginal secretion collection for metagenomic sequencing, cervical exfoliated cells for TCT and STI nucleic acid testing, and venous blood testing. No specific interventions will be administered.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of CIN2+ at 5 years

    The incidence rate of histologically confirmed Cervical Intraepithelial Neoplasia grade 2 or 3 (CIN2/3) or invasive cervical cancer occurring for the first time during the follow-up period, among participants who had no cervical lesions or were \<CIN2 at baseline

    Time frame: 5 years

Secondary outcomes

  1. New incidence and progression rates of ASC-US+ cytological abnormalities

    ASC-US+ new incidence: First occurrence of ASC-US or higher cytological abnormality during follow-up in participants with normal baseline cytology. ASC-US+ progression: First occurrence of LSIL/HSIL or higher cytological abnormality during follow-up in participants with baseline ASC-US. Cytology is evaluated according to the Bethesda System for Reporting Cervical Cytology.

    Time frame: 5 years

Other outcomes

  1. HPV and STI incidence, clearance, and persistent/recurrent infection rates

    HPV new infection: baseline negative, follow-up positive; HPV clearance: baseline positive, follow-up negative; HPV persistent infection: same genotype positive at both baseline and follow-up. STI new infection: baseline negative, follow-up positive; STI clearance: baseline positive, follow-up same genotype negative; STI recurrent infection: same genotype positive at both baseline and follow-up.

    Time frame: 5 years

07

Study locations

43 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 42 non-industry observational studies under Sexually Transmitted Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 18 months is below that.

Counting every sponsor, half of 48 studies reached it within 26 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 20, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941284
Lead sponsor
Shenzhen Maternity & Child Healthcare Hospital
Collaborators
Shenzhen Hospital of Southern Medical University, Peking University First Hospital, Fujian Maternity and Child Health Hospital, Gansu Provincial Hospital, First Affiliated Hospital of Guangxi Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Henan Provincial People's Hospital, Huizhou Municipal Central Hospital, LanZhou University, Lianyungang Hospital Affiliated Bengbu Medical College, The Fifth Affiliated Hospital of Southern Medical University, The Third Affiliated Hospital of Southern Medical University, Nanfang Hospital, Southern Medical University, Southern Medical University, China, General Hospital of Ningxia Medical University, Qinghai Red Cross Hospital, Jinan Central Hospital, Shandong Provincial Hospital, Changzhi People's Hospital, Shanghai East Hospital of Tongji University, Tibet Autonomous Region People's Hospital, The Affiliated Hospital Of Southwest Medical University, Yuebei People's Hospital, First Hospital of China Medical University, The Seventh Affiliated Hospital of Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Zhuhai Center for Maternal and Child Health Care, The First People's Hospital of Zunyi
Responsible party
Muxuan Chen (Deputy Director, Shenzhen Maternity & Child Healthcare Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 20, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Muxuan Chen, Doctor
Contact
muxuanchen@126.com
+8613580561916
Hongwei Zhou, Doctor
study chair · Shenzhen Hospital of Southern Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion